4//SEC Filing
Schorno Dean L 4
Accession 0000905148-24-000851
CIK 0001034842other
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 7:16 PM ET
Size
8.3 KB
Accession
0000905148-24-000851
Insider Transaction Report
Form 4
Schorno Dean L
EVP & Chief Financial Officer
Transactions
- Award
Employee Stock Option (right to buy)
2024-02-28+62,500→ 62,500 totalExercise: $1.87Exp: 2033-01-26→ Common Stock (62,500 underlying) - Award
Employee Stock Option (right to buy)
2024-02-28+78,500→ 78,500 totalExercise: $1.27Exp: 2034-01-23→ Common Stock (78,500 underlying)
Footnotes (3)
- [F1]The Reporting Person was granted an option with a performance-based condition with respect to 62,500 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met.
- [F2]The Reporting Person was granted an option with a performance-based condition with respect to 78,500 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met.
- [F3]The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met.
Documents
Issuer
RIGEL PHARMACEUTICALS INC
CIK 0001034842
Entity typeother
Related Parties
1- filerCIK 0001509688
Filing Metadata
- Form type
- 4
- Filed
- Feb 29, 7:00 PM ET
- Accepted
- Mar 1, 7:16 PM ET
- Size
- 8.3 KB